28 September 2023
Kromek Group plc
("Kromek" or the "Group")
Result of AGM
Kromek Group plc, a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its Annual General Meeting ("AGM"), held earlier today, all resolutions were duly passed.
Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:
| Resolution | Votes for | Votes against | Votes withheld | Total proxy votes | ||
| | No. of votes | % of votes cast* | No. of votes | % of votes cast* | No. of votes | |
| 1 | 189,476,538 | 94.43 | 11,176,883 | 5.57 | 217,336 | 200,870,757 |
| 2 | 179,826,325 | 90.14 | 19,674,285 | 9.86 | 1,370,147 | 200,870,757 |
| 3 | 182,008,714 | 91.33 | 17,274,285 | 8.67 | 1,587,758 | 200,870,757 |
| 4 | 198,554,316 | 99.71 | 582,433 | 0.29 | 1,734,008 | 200,870,757 |
| 5 | 199,638,889 | 99.60 | 806,687 | 0.40 | 425,181 | 200,870,757 |
| 6 | 198,643,359 | 98.98 | 2,051,977 | 1.02 | 175,421 | 200,870,757 |
| 7 | 191,067,728 | 96.32 | 7,295,934 | 3.68 | 2,507,095 | 200,870,757 |
| 8 | 187,184,965 | 93.34 | 13,353,050 | 6.66 | 332,742 | 200,870,757 |
*Excludes withheld votes
For further information, please contact:
| Kromek Group plc | |
| Arnab Basu, CEO Paul Farquhar, CFO | +44 (0)1740 626 060 |
|
| |
| Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
| Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern/Charlotte Sutcliffe - ECM | +44 (0)20 7220 0500
|
| Michael Johnson/Tamar Cranford-Smith - Sales
| |
| Gracechurch Group (Financial PR) | |
| Harry Chathli/Claire Norbury/Henry Gamble | +44 (0)20 4582 3500 |
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.